Howell D A, Wang H-I, Roman E, Smith A G, Patmore R, Johnson M J, Garry A C, Howard M R
Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, North Yorkshire, UK.
Queens Centre for Oncology, Castle Hill Hospital, Hull, East Yorkshire, UK.
BMJ Support Palliat Care. 2015 Dec;5(5):496-502. doi: 10.1136/bmjspcare-2013-000578. Epub 2014 Feb 19.
To develop and implement a methodology for capturing complete haematological malignancy pathway data and use it to identify variations in specialist palliative care (SPC) referrals.
In our established UK population-based patient cohort, 323 patients were diagnosed with acute myeloid leukaemia, diffuse large B-cell lymphoma or myeloma between May 2005 and April 2008, and died before April 2010. A day-by-day calendar approach was devised to collect pathway data, including SPC referrals, to supplement routinely collected information on clinical presentation, diagnosis, treatment, response, and date and place of death.
155 (47.9%) of the 323 patients had at least one SPC referral. The likelihood of referral increased with survival (OR 6.58, 95% CIs 3.32 to 13.03 for patients surviving ≥1 year compared to ≤1 month from diagnosis), and varied with diagnosis (OR 1.96, CIs 1.15 to 3.35 for myeloma compared to acute myeloid leukaemia). Compared to patients dying in hospital, those who died at home or in a hospice were also more likely to have had an SPC referral (OR 3.07, CIs 1.59 to 5.93 and 4.74, CIs 1.51 to 14.81, respectively). No associations were found for age and sex.
Our novel approach efficiently captured pathway data and SPC referrals, revealing evidence of greater integration between haematology and SPC services than previously reported. The likelihood of referral was much higher among those dying outside hospital, and variations in practice were observed by diagnosis, emphasising the importance of examining diseases individually.
开发并实施一种用于获取完整血液系统恶性肿瘤诊疗路径数据的方法,并利用该方法识别专科姑息治疗(SPC)转诊的差异。
在我们已建立的基于英国人群的患者队列中,2005年5月至2008年4月期间有323例患者被诊断为急性髓系白血病、弥漫性大B细胞淋巴瘤或骨髓瘤,并于2010年4月前死亡。设计了一种逐日日历法来收集诊疗路径数据,包括SPC转诊,以补充常规收集的关于临床表现、诊断、治疗、反应以及死亡日期和地点的信息。
323例患者中有155例(47.9%)至少有一次SPC转诊。转诊的可能性随生存期增加(与诊断后≤1个月相比,诊断后存活≥1年的患者的比值比为6.58,95%可信区间为3.32至13.03),且因诊断而异(与急性髓系白血病相比,骨髓瘤的比值比为1.96,可信区间为1.15至3.35)。与在医院死亡的患者相比,在家中或临终关怀机构死亡的患者也更有可能接受过SPC转诊(分别为比值比3.07,可信区间为1.59至5.93和比值比4.74,可信区间为1.51至14.81)。未发现年龄和性别之间存在关联。
我们的新方法有效地获取了诊疗路径数据和SPC转诊信息,揭示了血液学和SPC服务之间比以前报道的有更大整合的证据。在院外死亡的患者中转诊的可能性要高得多,并且在实践中观察到因诊断而异,强调了对疾病进行个体检查的重要性。